Assembly Biosciences(ASMB) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates • Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and oncemonthly oral dosing • First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025 • Phase 1b trial for ABI-4334, a next-generation ...